WAVE Life Sciences (NASDAQ:WVE) Price Target Lowered to $27.00 at Wells Fargo & Company

WAVE Life Sciences (NASDAQ:WVE) had its target price reduced by Wells Fargo & Company from $29.00 to $27.00 in a report published on Thursday, MarketBeat Ratings reports. Wells Fargo & Company currently has an overweight rating on the stock.

WVE has been the topic of several other reports. UBS Group set a $32.00 target price on shares of WAVE Life Sciences in a research note on Tuesday, December 16th. Bank of America assumed coverage on WAVE Life Sciences in a report on Thursday, February 5th. They set a “buy” rating and a $38.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, January 21st. HC Wainwright raised their price objective on WAVE Life Sciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, Cantor Fitzgerald lifted their target price on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.56.

WAVE Life Sciences Trading Down 3.5%

WVE stock opened at $12.80 on Thursday. WAVE Life Sciences has a one year low of $5.28 and a one year high of $21.73. The firm has a 50-day moving average of $15.09 and a two-hundred day moving average of $10.39. The firm has a market capitalization of $2.14 billion, a PE ratio of -17.07 and a beta of -1.78.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The firm had revenue of $7.61 million during the quarter, compared to analysts’ expectations of $9.85 million. WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%. On average, equities research analysts anticipate that WAVE Life Sciences will post -1.14 earnings per share for the current year.

Insider Activity

In other WAVE Life Sciences news, Director Adrian Rawcliffe sold 42,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.00, for a total transaction of $630,000.00. Following the completion of the sale, the director directly owned 12,700 shares in the company, valued at $190,500. This represents a 76.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Chris Francis sold 441,031 shares of WAVE Life Sciences stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $14.57, for a total value of $6,425,821.67. Following the completion of the transaction, the insider owned 25,000 shares in the company, valued at $364,250. The trade was a 94.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 915,181 shares of company stock worth $13,612,581. Insiders own 23.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of WAVE Life Sciences by 9.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after acquiring an additional 4,957 shares during the period. Goldman Sachs Group Inc. increased its position in WAVE Life Sciences by 3.8% during the first quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock worth $4,506,000 after acquiring an additional 20,624 shares during the period. TD Asset Management Inc raised its stake in WAVE Life Sciences by 16.3% during the 2nd quarter. TD Asset Management Inc now owns 179,608 shares of the company’s stock valued at $1,167,000 after purchasing an additional 25,200 shares during the last quarter. Privium Fund Management B.V. raised its stake in WAVE Life Sciences by 19.4% during the 2nd quarter. Privium Fund Management B.V. now owns 135,550 shares of the company’s stock valued at $884,000 after purchasing an additional 22,000 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in WAVE Life Sciences by 8.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 28,955 shares of the company’s stock valued at $188,000 after purchasing an additional 2,206 shares during the period. 89.73% of the stock is owned by institutional investors.

Key Stories Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wells Fargo kept an “overweight” rating on WVE and set a $27 price target (down from $29), which still implies substantial upside versus the current share price — a signal that some sell‑side analysts remain constructive on the company’s pipeline and long‑term prospects. The Fly: Wells Fargo price target note
• Positive Sentiment: Broader analyst coverage remains favorable — multiple firms have upgraded or raised targets in recent months and the consensus remains skewed toward Buy/Outperform, supporting potential upside if clinical progress continues. MarketBeat analyst roundup
• Neutral Sentiment: Institutional ownership is very high (~90%), which means large holders dominate supply — that can both support the stock during positive news and amplify moves when those holders change positions.
• Negative Sentiment: Multiple insiders sold shares on Feb 9 (CEO Paul Bolno, CFO Kyle Moran, and other officers/directors), executing sizable sales at roughly $13.45 per share — the cluster of top‑executive sales is being viewed negatively by the market as a potential signal of near‑term insider liquidity. InsiderTrades alert
• Negative Sentiment: WAVE’s last reported quarter missed estimates (EPS and revenue) and the company remains unprofitable with wide negative margins — ongoing cash burn and execution risk keep the shares sensitive to clinical and revenue updates. MarketBeat: earnings summary

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.